In the past week, AVDL stock has gone up by 2.53%, with a monthly gain of 9.73% and a quarterly surge of 29.88%. The volatility ratio for the week is 5.17%, and the volatility levels for the last 30 days are 5.78% for Avadel Pharmaceuticals plc The simple moving average for the last 20 days is 5.07% for AVDL’s stock, with a simple moving average of 30.95% for the last 200 days.
Is It Worth Investing in Avadel Pharmaceuticals plc (NASDAQ: AVDL) Right Now?
The 36-month beta value for AVDL is at 1.62. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVDL is 70.65M, and currently, shorts hold a 14.71% of that float. The average trading volume for AVDL on April 26, 2024 was 1.22M shares.
AVDL) stock’s latest price update
The stock of Avadel Pharmaceuticals plc (NASDAQ: AVDL) has increased by 0.91 when compared to last closing price of 17.66.Despite this, the company has seen a gain of 2.53% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-02 that Avadel Pharmaceuticals reports strong Q4 2023 earnings for Lumryz, its once-nightly formulation of sodium oxybate for narcolepsy. Lumryz fills a significant gap in narcolepsy treatment by offering a more patient-friendly dosing schedule and improving compliance and patient outcomes. Legal developments, including a favorable jury ruling on patent litigation, reduce legal overhang and instill investor confidence in Avadel’s ability to navigate challenges.
Analysts’ Opinion of AVDL
Many brokerage firms have already submitted their reports for AVDL stocks, with Oppenheimer repeating the rating for AVDL by listing it as a “Outperform.” The predicted price for AVDL in the upcoming period, according to Oppenheimer is $29 based on the research report published on March 05, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see AVDL reach a price target of $22, previously predicting the price at $20. The rating they have provided for AVDL stocks is “Buy” according to the report published on March 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to AVDL, setting the target price at $25 in the report published on March 05th of the current year.
AVDL Trading at 13.15% from the 50-Day Moving Average
After a stumble in the market that brought AVDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.46% of loss for the given period.
Volatility was left at 5.78%, however, over the last 30 days, the volatility rate increased by 5.17%, as shares surge +5.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.94% upper at present.
During the last 5 trading sessions, AVDL rose by +2.53%, which changed the moving average for the period of 200-days by +14.97% in comparison to the 20-day moving average, which settled at $17.01. In addition, Avadel Pharmaceuticals plc saw 26.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVDL starting from MCHUGH THOMAS S, who purchase 2,000 shares at the price of $14.50 back on Jan 16 ’24. After this action, MCHUGH THOMAS S now owns 80,500 shares of Avadel Pharmaceuticals plc, valued at $29,000 using the latest closing price.
McCamish Mark Anthony, the Director of Avadel Pharmaceuticals plc, sale 75,000 shares at $14.53 during a trade that took place back on Dec 28 ’23, which means that McCamish Mark Anthony is holding 67,025 shares at $1,089,750 based on the most recent closing price.
Stock Fundamentals for AVDL
Current profitability levels for the company are sitting at:
- -4.93 for the present operating margin
- 0.95 for the gross margin
The net margin for Avadel Pharmaceuticals plc stands at -5.73. The total capital return value is set at -0.61. Equity return is now at value -481.35, with -68.90 for asset returns.
Based on Avadel Pharmaceuticals plc (AVDL), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -3.81. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -13.94.
Currently, EBITDA for the company is -136.08 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 57.87. The receivables turnover for the company is 2.08for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.64.
Conclusion
In conclusion, Avadel Pharmaceuticals plc (AVDL) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
